Lyra Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 145
- Market Cap
- $21.6M
Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (ENLIGHTEN 2)
Phase 3
Active, not recruiting
- Conditions
- Chronic SinusitisChronic Rhinosinusitis (Diagnosis)
- Interventions
- Drug: Sham procedure controlDrug: LYR-210Other: Background therapy
- First Posted Date
- 2022-03-25
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Lyra Therapeutics
- Target Recruit Count
- 182
- Registration Number
- NCT05295459
- Locations
- 🇺🇸
Novak Clinical Trials, Tucson, Arizona, United States
🇺🇸Keck School of Medicine at USC Medical Center, Arcadia, California, United States
🇺🇸Sensa Health Clinical Research, Los Angeles, California, United States
Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults
Phase 3
Active, not recruiting
- Conditions
- Chronic SinusitisChronic Rhinosinusitis (Diagnosis)
- Interventions
- Drug: LYR-210Drug: Sham procedure controlOther: Background Therapy
- First Posted Date
- 2022-02-02
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Lyra Therapeutics
- Target Recruit Count
- 196
- Registration Number
- NCT05219968
- Locations
- 🇪🇸
Lyra Investigational Site, Santander, Spain
LYR-220 for Adult Subjects With Chronic Rhinosinusitis (BEACON Study)
Phase 2
Completed
- Conditions
- Chronic SinusitisChronic Rhinosinusitis (Diagnosis)
- Interventions
- Drug: LYR-220 Design 1 (Part 1 only)Drug: LYR-220 Design 2 (Part 1 and Part 2)Drug: Bilateral sham procedure control (Part 2)
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Lyra Therapeutics
- Target Recruit Count
- 48
- Registration Number
- NCT05035654
- Locations
- 🇦🇺
Lyra Investigational Site, Melbourne, Australia
LYR-210 Depot (LYR-210) for Adult Subjects With Chronic Sinusitis (LANTERN Study)
Phase 2
Completed
- Conditions
- Chronic SinusitisChronic Rhinosinusitis (Diagnosis)
- Interventions
- Drug: LYR-210Other: Sham comparator
- First Posted Date
- 2019-08-01
- Last Posted Date
- 2023-07-25
- Lead Sponsor
- Lyra Therapeutics
- Target Recruit Count
- 71
- Registration Number
- NCT04041609
- Locations
- 🇵🇱
Provita Sp. z o.o. Centrum Medyczne Angelius Provita, Katowice, Poland
🇵🇱Centrum Medyczne PROMED, Kraków, Poland
🇵🇱Vistamed Sp. z o.o., Wrocław, Poland
480 Biomedical Sinus Drug Depot
Phase 1
Completed
- Conditions
- Chronic Sinusitis
- Interventions
- Drug: 480 Mometasone Furoate Sinus Drug Depot
- First Posted Date
- 2016-11-18
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- Lyra Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT02967731
- Locations
- 🇳🇿
University of Auckland, Auckland, New Zealand
🇦🇺Royal Brisbane and Women's Hospital, Brisbane, Australia
🇦🇺Monash Medical Center, Melbourne, Australia
© Copyright 2025. All Rights Reserved by MedPath